Everything below concerns circadian rhythm. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-07-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
| Property | Value | Notes |
|---|---|---|
| Synonyms | SR9009; Stenabolic | Stenabolic is an informal name |
| Common form | Crystalline powder | Supplied in milligram to gram quantities |
| Long-term storage | -20 °C, desiccated, protected from light | Reduces degradation |
| Detection technique | LC-MS/MS | Common in anti-doping and research analysis |
| Regulatory status | Prohibited in sport by WADA | Not approved for human therapeutic use |
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
=== Komagataella as an experimental model organism === As an experimental model organism, Komagataella was mainly used as the host system for transformation. Due to its abilities of recombination with foreign DNA and processing large proteins, much research has been carried out to investigate the possibility of producing new proteins and the function of artificially designed proteins, using Komagataella as a transformation host. In the last decade, Komagataella was engineered to build expression system platforms, which is a typical application for a standard experimental model organism, as described below.
In 1981 Channon left Guy's Hospital to continue his work with Drs Martin Hartog and Richard Paisey at the Bristol Royal Infirmary. Channon then developed the miniature Portaject device. Unlike the Multiject the Portaject is designed to be worn. It has the capacity for sufficient insulin for 24 hours (at the time insulin had to be refrigerated; at room or body temperature it would become unusable after 24 hours). Channon self-funded the design and fabrication work through his company Channon Medical Ltd. He filed a patent for the Portaject in 1988 but subsequently withdrew the application, choosing instead to donate his research to the field. Clinical trials at the BRI were supported by a small grant of £4,500 from the National Medical Research fund. Dr Hartog attests that "Portaject was the first device that allowed convenient repeated subcutaneous injections of insulin and led to the Novopen. Administration of insulin in this way resulted in a much improved control of the patient's diabetes and, consequently, to a considerably improved prognosis overall". Dr Paisey recalls that clinical trials were conducted with 20 patients and that "one of them continued for 20 years with the same device and achieved good glycemic control. He also designed and manufactured a belt to house the pump". Another long term user, Stephen Dixon, wrote to Channon "Thanks so much for doing what you did. You truly helped transform millions of lives, including mine". In 1989 Channon developed a simple device for protecting, lubricating and sterilizing a hypodermic needle.
== Science, medicine and technology == Na D, a spectroscopic line due to sodium Network Access Device, a device in mobile phones that finds the shortest route for a connection Nicotinamide adenine dinucleotide, a coenzyme and signaling molecule No acute distress, on physical exam Noradrenalin, a hormone and neurotransmitter Nucleolar-associating domains (NADs); regions of the chromosome that interact with the nucleolus
As of 2017, lithium was marketed under many brand names worldwide, including Cade, Calith, Camcolit, Carbolim, Carbolit, Carbolith, Carbolithium, Carbonato de Litio, Carboron, Ceglution, Contemnol, Efadermin (Lithium and Zinc Sulfate), Efalith (Lithium and Zinc Sulfate), Elcab, Eskalit, Eskalith, Frimania, Hypnorex, Kalitium, Karlit, Lalithium, Li-Liquid, Licarb, Licarbium, Lidin, Ligilin, Lilipin, Lilitin, Limas, Limed, Liskonum, Litarex, Lithane, Litheum, Lithicarb, Lithii carbonas, Lithii citras, Lithioderm, Lithiofor, Lithionit, Lithium, Lithium aceticum, Lithium asparagicum, Lithium Carbonate, Lithium Carbonicum, Lithium Citrate, Lithium DL-asparaginat-1-Wasser, Lithium gluconicum, Lithium-D-gluconat, Lithiumcarbonaat, Lithiumcarbonat, Lithiumcitrat, Lithiun, Lithobid, Lithocent, Lithotabs, Lithuril, Litiam, Liticarb, Litijum, Litio, Litiomal, Lito, Litocarb, Litocip, Maniprex, Milithin, Neurolepsin, Plenur, Priadel, Prianil, Prolix, Psicolit, Quilonium, Quilonorm, Quilonum, Sedalit, Téralithe, and Theralite. Lithium is available as lithium carbonate in tablets or capsules, and as lithium citrate in liquid form. In the United States, standard release tablets are available in 300 mg. Standard release capsules come in strengths of 150 mg, 300 mg, and 600 mg. Slow release tablets are available in 300 mg and 450 mg. Liquid lithium, in the form of lithium citrate, is available as an 8 mEq/5 mL solution. In the United Kingdom, lithium is available as standard release tablets of 250 mg, while slow release tablets come in 200 mg, 400 mg and 450 mg.
==== Skin and chronic wounds ==== Dermal regeneration involves the development of bioengineered skin substitutes and advanced wound dressings to treat deep third-degree burns, diabetic foot ulcers, and extensive chronic wounds. Unlike traditional occlusive dressings, regenerative skin scaffolds provide a temporary, porous extracellular matrix analog that coordinates cellular ingress, granulation tissue formation, and re-epithelialization. Commercially available matrices utilize decellularized human or bovine dermal matrices, synthetic biodegradable polymers (such as polycaprolactone), and naturally derived marine biomaterials, including acellular fish skin graphics rich in omega-3 fatty acids. These matrices are designed to modulate the localized inflammatory response, suppress bacterial colonization, and recruit host fibroblasts and keratinocytes to restore functional, vascularized skin tissue while minimizing scar formation.
Sources: en.wikipedia.org
== History == After its initial US FDA approval, due to the pro-arrhythmic potential, it was only made available to hospitals and prescribers that had received education and undergone specific training in the risks of treatment with dofetilide; however, this restriction was subsequently removed in 2016.
The Lab is a VR game developed by Valve that as part of its partnership with HTC and the VR headset, the HTC Vive. It was described as a "room-scale" VR experience, consisting of about a dozen small experimental experiences that highlight the use of VR; such include experiencing a fully panoramic view that has been stitched together from a number of photographs, a physics game where the player attempts to launch personality cores into piles of boxes using a catapult, and a bow-and-arrow based game. The Lab was announced at the 2016 Game Developers Conference, and was released free on April 5, 2016, following the public release of the HTC Vive.
Thomas's home in Laugharne, the Boathouse, is a museum run by Carmarthenshire County Council. His writing shed is also preserved. In 2004, the Dylan Thomas Prize was created in his honour, awarded to the best published writer in English under the age of 30. In 2005, the Dylan Thomas Screenplay Award was established. The prize, administered by the Dylan Thomas Centre, is awarded at the annual Swansea Bay Film Festival. In 1982 a plaque was unveiled in Poets' Corner, Westminster Abbey. The plaque is also inscribed with the last two lines of "Fern Hill". In 2014, the Royal Patron of The Dylan Thomas 100 Festival was Charles, Prince of Wales, who in 2013 made a recording of "Fern Hill" for National Poetry Day. In 2014, to celebrate the centenary of Thomas's birth, the British Council Wales undertook a year-long programme of cultural and educational works. Highlights included a touring replica of Thomas's work shed, Sir Peter Blake's exhibition of illustrations based on Under Milk Wood and a 36-hour marathon of readings, which included Michael Sheen and Sir Ian McKellen performing Thomas's work. The same year, Thomas was among the ten people commemorated on a UK postage stamp issued by the Royal Mail in their "Remarkable Lives" issue.
Bully: Tayfun Dasdemir Height: 5'11 Weight: 341 lb Victim(s): Chuckie, Yunas Fighter: Nick Gaston Height: 6'5 Weight: 266 lb Money earned by Bully: $0 Money earned by victim(s): $10,000 Original airing: This episode was aired on MTV Canada on March 7, 2011. This episode aired on September 28, 2012 on MTV 2.
Sources: en.wikipedia.org
Laboratories commonly use liquid chromatography coupled with mass spectrometry to detect SR9009. The method can identify the compound and estimate concentration in a sample. Detection limits depend on the matrix and instrument.
Research-grade purity indicates a supplier's measured percentage of the intended compound. It does not guarantee safety, sterility, or suitability for human consumption. Buyers should request a certificate of analysis with chromatograms and test methods.
Sports regulators prohibit SR9009 because it is a non-approved substance with potential performance-altering effects. Its presence can be detected in anti-doping testing. Athletes are responsible for substances found in their samples.
Liquid chromatography–mass spectrometry is common for identity and purity checks. High-performance liquid chromatography with ultraviolet detection can also be used. Both methods require a suitable reference standard.